, Albert J. Chang1, Alexander R. Gottschalk1 and Mack RoachIII2 (1) Department of Radiation Oncology, University of California San Francisco, 1600 Divisadero Street, Suite H1031, San Francisco, CA, USA (2) Department of Radiation Oncology and…
Disease site Presentation Recommended treatment Extremity Early stage (I) Surgery->EBRT for +/close margin Intermediate-advanced stage (II–III) Surgery->post-op EBRT or pre-op EBRT->surgery, ±chemo for deep/high grade tumors Retroperi-toneal Resectable Surgery + IORT- >post-op…
Study Year Number of patients Primary site Treated site Dose Local control Overall survival Toxicity Casamassima 2012 48 Multiple Adrenal Most common 36 Gy/3 fractions 90 % (2 years) 40…
Presentation Treatment recommendations Isolated lateral pelvic recurrences Resection, palliative EBRT, SBRT, or systemic therapy Isolated nodal recurrence Resection, EBRT ± SBRT, SBRT alone, or systemic therapy Oligometastatic disease Resection, SBRT, or…
(2.1) In its simplest form, differences in tissue or tumor responses can be calculated using BED, the biologically effective dose, obtained from a fraction size of dose d delivered n…
© Springer International Publishing Switzerland 2016Rajni A. Sethi, Igor J. Barani, David A. Larson and Mack Roach, III (eds.)Handbook of Evidence-Based Stereotactic Radiosurgery and Stereotactic Body Radiotherapy10.1007/978-3-319-21897-7_6 6. Head and Neck Sue S. Yom1 (1) Department of Radiation Oncology,…
Class Characteristics Survival (months) I KPS 70–100 7.1 Age <65 Primary tumor controlled Metastases to brain only II All others 4.2 III KPS <70 2.3 Meningioma Thirty-percent of primary intracranial…
Characteristic Conventional RT SRS/ SBRT Prescription dose per fraction ≤3 Gy ≥5 Gy Number of fractions ≥10 ≤5 Dose distribution Homogeneous (max PTV dose ≈105–110 %) Heterogeneous (max PTV dose…
